在英格兰婴儿1+1免疫程序中以15价或20价肺炎球菌结合疫苗替代13价肺炎球菌结合疫苗的潜在影响:一项模型研究
该模型研究基于英格兰PCV7和PCV13引入前后的携带与侵袭性肺炎球菌病数据,模拟婴儿1+1程序中以PCV15或PCV20替代PCV13的影响。结果提示PCV15可能因非PCV15侵袭性肺炎球菌病增加而总体增加侵袭性肺炎球菌病,PCV20则可能大幅降低总体疾病负担。
要点
- 基于英格兰数据的模型提示,PCV15可能因非PCV15侵袭性肺炎球菌病增加而总体增加侵袭性肺炎球菌病。
- PCV20因额外血清型侵袭性高于替代的非疫苗血清型,预计对总体侵袭性肺炎球菌病有大幅影响。
- 高效价疫苗对PCV13血清型携带保护减弱会放大上述效应。
核心结论
- 以PCV20替代PCV13可能带来大幅公共卫生获益,但PCV15可能增加总体疾病负担。
研究设计与样本
- 模型研究,采用现实年龄结构确定性房室模型,拟合英格兰PCV引入前携带数据及PCV7和PCV13引入前后侵袭性肺炎球菌病监测数据。
- 模拟在当前1+1免疫程序下婴儿由PCV13转换为PCV15或PCV20的效果,并考察高效价疫苗免疫原性减弱致PCV13血清型携带保护降低的影响。
主要发现
- PCV15可能增加总体侵袭性肺炎球菌病,因疫苗型侵袭性肺炎球菌病减少被非PCV15侵袭性肺炎球菌病增加所抵消。
- PCV20预计对总体侵袭性肺炎球菌病有大幅影响,因PCV20覆盖的额外血清型侵袭性高于替代的非疫苗血清型。
- 高效价疫苗对PCV13血清型携带保护降低会放大上述效应。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Paediatric pneumococcal conjugate vaccine (PCV) programmes in England using seven-valent PCV (PCV7) in 2006 and 13-valent PCV (PCV13) in 2010 have reduced vaccine-type invasive pneumococcal disease, but the overall effect has been reduced by an increase in invasive pneumococcal disease due to non-vaccine serotypes and serotype 3. We developed pneumococcal transmission models to investigate the potential effect on invasive pneumococcal disease of higher valency PCVs covering an additional two (ie, 15-valent PCV [PCV15]) or seven serotypes (ie, 20-valent PCV [PCV20]) in England. METHODS: We conducted a modelling study using realistic, age-structured, and compartmental deterministic models fitted to carriage data from before the introduction of PCVs and invasive pneumococcal disease data from before and after the introduction of PCV7 and PCV13 in England from the UK Heath Security Agency invasive pneumococcal disease surveillance system. We estimated key parameters, including PCV7 and PCV13 efficacy against vaccine-type carriage and invasiveness of PCV7 serotypes; the additional serotypes in PCV13, PCV15 and PCV20; and non-vaccine serotypes. We simulated the effect of transitioning from PCV13 to PCV15 or PCV20 in infants under the current 1 + 1 vaccination schedule and investigated the effect of reduced carriage protection against PCV13 serotypes due to attenuation of immunogenicity in higher valency vaccines. FINDINGS: Our results suggest that PCV15 might increase overall invasive pneumococcal disease as the reduction in vaccine-type invasive pneumococcal disease would be counterbalanced by an increase in non-PCV15 invasive pneumococcal disease. By contrast, PCV20 is projected to have a substantial impact on overall invasive pneumococcal disease due to higher invasiveness of the additional serotypes covered by PCV20 than the replacing non-vaccine serotypes. Reduced carriage protection against PCV13 serotypes with higher valency vaccines would amplify these effects. INTERPRETATION: Replacing PCV13 with PCV20 is likely to have a substantial public health benefit, but PCV15 could potentially increase the overall burden of disease. FUNDING: UK Health Security Agency and National Institute of Health Research.
引用
- Choi YH, Bertran M, Litt DJ, et al. Potential impact of replacing the 13-valent pneumococcal conjugate vaccine with 15-valent or 20-valent pneumococcal conjugate vaccine in the 1 + 1 infant schedule in England: a modelling study. Lancet Public Health. 2024. PMID: 39153492. doi:10.1016/S2468-2667(24)00161-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。